Novo Nordisk Threatens Legal Action Against Hims & Hers Over Compounded Wegovy Pill

• Hims & Hers is engaging in “illegal mass compounding,” Novo said.  
• Novo and Hims had a partnership in 2025 allowing the telehealth company to offer injectable Wegovy but the deal was called off within months.
• Novo on Wednesday said that it now expects adjusted sales to fall between 5% and 13%, and operating profit could decline by up to 13% in 2026.

Danish drugmaker Novo Nordisk (NVO) said on Thursday that it will pursue “legal and regulatory” actions against Hims & Hers (HIMS) after the latter launched a compounded copy of Novo’s best-selling weight loss pill.

Earlier in the day, Hims launched a copy of the Wegovy pill with an introductory price of $49 per month, much below the branded drug. The online telehealth company said the compounded copy uses the same active ingredient as Wegovy. The company already offers a compounded version of injectable Wegovy.

“This is another example of Hims & Hers' historic behaviour of duping the American public with knock-off GLP-1 products,” Novo said in a statement, while adding that Hims & Hers is engaging in “illegal mass compounding.”

Novo also noted that it only makes FDA-approved Wegovy pills which was launched in early January. The weight-loss drug has had a great kickstart so far.  

NVO shares traded 6% lower at the time of writing, while HIMS stock pared gains made earlier in the day to trade about 2% lower.

Novo-Hims Past Partnership

Novo and Hims had a partnership in 2025, allowing the telehealth company to offer injectable Wegovy. However, the deal was called off within months. Novo said that Hims & Hers failed to adhere to the law, which prohibits mass sales of compounded drugs. It alleged that the telehealth operator is promoting and selling illegitimate, knockoff versions of Wegovy.

Meanwhile, Hims CEO Andrew Dudum, alleged that Novo management is “misleading the public.”

Novo’s Disappointing Outlook

Novo on Wednesday said that it now expects adjusted sales to fall between 5% and 13%, and operating profit could decline by up to 13% in 2026.

The company flagged concerns including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S. behind the disappointing guidance.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around HIMS stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.

Meanwhile, sentiment around NVO stock fell from ‘extremely bullish’ to ‘bullish’ levels.

HIMS stock has dropped 44% over the past 12 months, while NVO shares dropped 48%. 

Also See: Ross Gerber Warns Of Intense Hardware Battle As AI Spending Sparks Competition Among Tech Leaders

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on